Compound ID | 1860
Synonym(s): Rifamycin SV | Rifocin | Aemcolo
Class: Rifamycin
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Inhibits bacterial DNA-dependent RNA polymerase, thus inhibiting bacterial RNA synthesis |
| Propensity to select resistant mutants: | Yes |
| Description: | Streptomyces natural compound (Amycolatopsis rifamycinica). Used for traveler's diarrhea in oral formulation |
| Institute where first reported: | Cosmo Technologies Ltd, Dr. Falk Pharma Gmbh;; Redhill |
| Year first mentioned: | 1957 |
| Highest development stage: | Approved by FDA in 2018 |
| Development status: | Discontinued |
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/6324616 |
| Guide to Pharmacology: | rifamycin |
| Citations: |
|